Human Metapneumovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Infection

Date 2012 Jul 18

PMID 22802096

Citations 20

Authors

A Egli

C Bucher

A Dumoulin

M Stern

A Buser

L Bubendorf

M Gregor

P Servida

G Sommer

J Bremerich

A Gratwohl

N Khanna

A F Widmer

M Battegay

M Tamm

H H Hirsch

J P Halter

Affiliations

Soon will be listed here.

Abstract

Background: The clinical characteristics of human metapneumovirus (hMPV)-associated lower respiratory tract infection (LRTI) after allogeneic hematopoietic stem cell transplantation (HSCT) is not well described. We describe the clinical course in eight HSCT recipients suffering from hMPV infection.

Methods: We prospectively included all patients with hMPV-associated LRTI after allogeneic HSCT during a period of 1 year. hMPV was diagnosed by multiplex polymerase chain reaction (PCR) from bronchoalveolar lavage (BAL).

Results: Eight patients with hMPV-associated LRTI were identified from 93 BAL samples. Three of the eight patients had co-infections with other pathogens. The median age of the patients was 45 years [interquartile range (IQR) 36.8-53.5], the median time posttransplant was 473 days (IQR 251-1,165), 5/8 patients had chronic graft-versus-host disease (cGvHD), and 6/8 patients received immunosuppression. Chest computed tomography (CT) scanning showed a ground-glass pattern in 7/8 patients. Seven of eight patients required hospitalization due to severe symptoms and hypoxemia. All were treated with intravenous immunoglobulin (IVIG), which was combined with oral ribavirin in six patients. The mortality rate was 12.5 % (1/8).

Conclusions: hMPV-associated LRTI in allogeneic HSCT recipients are not uncommon and present with unspecific respiratory symptoms, ground-glass pattern in CT scanning, and co-infection.

Citing Articles

Viruses and atypical bacteria in the respiratory tract of immunocompromised and immunocompetent patients with airway infection.

Reckziegel M, Weber-Osel C, Egerer R, Gruhn B, Kubek F, Walther M Eur J Clin Microbiol Infect Dis. 2020; 39(8):1581-1592.

PMID: 32462500 PMC: 7253234. DOI: 10.1007/s10096-020-03878-9.

Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs.

Ison M, Hirsch H Clin Microbiol Rev. 2019; 32(4).

PMID: 31511250 PMC: 7399564. DOI: 10.1128/CMR.00042-19.

Superinfection and cell regeneration can lead to chronic viral coinfections.

Pinky L, Gonzalez-Parra G, Dobrovolny H J Theor Biol. 2019; 466:24-38.

PMID: 30639572 PMC: 7094138. DOI: 10.1016/j.jtbi.2019.01.011.

Prophylactic and therapeutic approaches for human metapneumovirus.

Kumar P, Srivastava M Virusdisease. 2018; 29(4):434-444.

PMID: 30539045 PMC: 6261883. DOI: 10.1007/s13337-018-0498-5.

Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.

Spahr Y, Tschudin-Sutter S, Baettig V, Compagno F, Tamm M, Halter J Open Forum Infect Dis. 2018; 5(5):ofy077.

PMID: 29780847 PMC: 5952916. DOI: 10.1093/ofid/ofy077.

References

Chatzidimitriou D, Gavriilaki E, Sakellari I, Diza E . Hematopoietic cell transplantation and emerging viral infections. J Med Virol. 2010; 82(3):528-38. PMC: 7166846. DOI: 10.1002/jmv.21696. View

Hamelin M, Prince G, Boivin G . Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006; 50(2):774-7. PMC: 1366914. DOI: 10.1128/AAC.50.2.774-777.2006. View

Anderson E . Viral diagnostics and antiviral therapy in hematopoietic stem cell transplantation. Curr Pharm Des. 2008; 14(20):1997-2010. DOI: 10.2174/138161208785061364. View

Lacey S, Diamond D, Zaia J . Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant. 2004; 10(7):433-47. DOI: 10.1016/j.bbmt.2003.12.004. View

Huck B, Egger M, Bertz H, Peyerl-Hoffman G, Kern W, Neumann-Haefelin D . Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. J Clin Microbiol. 2006; 44(6):2300-3. PMC: 1489415. DOI: 10.1128/JCM.00152-06. View

Safdar A . Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant. 2008; 41(8):707-8. DOI: 10.1038/bmt.2008.80. View

Bonney D, Razali H, Turner A, Will A . Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol. 2009; 145(5):667-9. DOI: 10.1111/j.1365-2141.2009.07654.x. View

Campbell A, Chien J, Kuypers J, Englund J, Wald A, Guthrie K . Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis. 2010; 201(9):1404-13. PMC: 2853730. DOI: 10.1086/651662. View

Fischer S . Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation. 2008; 86(10):1327-39. DOI: 10.1097/TP.0b013e31818b6548. View

10.

Englund J, Boeckh M, Kuypers J, Nichols W, Hackman R, Morrow R . Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006; 144(5):344-9. DOI: 10.7326/0003-4819-144-5-200603070-00010. View

11.

Khanna N, Widmer A, Decker M, Steffen I, Halter J, Heim D . Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008; 46(3):402-12. DOI: 10.1086/525263. View

12.

Cane P, van den Hoogen B, Chakrabarti S, Fegan C, Osterhaus A . Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant. 2003; 31(4):309-10. DOI: 10.1038/sj.bmt.1703849. View

13.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

14.

Papenburg J, Boivin G . The distinguishing features of human metapneumovirus and respiratory syncytial virus. Rev Med Virol. 2010; 20(4):245-60. DOI: 10.1002/rmv.651. View

15.

Russmann S, Grattagliano I, Portincasa P, Palmieri V, Palasciano G . Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006; 13(27):3351-7. DOI: 10.2174/092986706778773059. View

16.

Ljungman P, Ward K, Crooks B, Parker A, Martino R, Shaw P . Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001; 28(5):479-84. DOI: 10.1038/sj.bmt.1703139. View

17.

Dumoulin A, Widmer A, Hirsch H . Comprehensive diagnostics for respiratory virus infections after transplantation or after potential exposure to swine flu A/H1N1: what else is out there?. Transpl Infect Dis. 2009; 11(4):287-9. PMC: 7169697. DOI: 10.1111/j.1399-3062.2009.00425.x. View

18.

Oliveira R, Machado A, Tateno A, Boas L, Pannuti C, Machado C . Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. Bone Marrow Transplant. 2008; 42(4):265-9. DOI: 10.1038/bmt.2008.153. View

19.

Boeckh M . The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008; 143(4):455-67. PMC: 2735199. DOI: 10.1111/j.1365-2141.2008.07295.x. View

20.

Franquet T, Rodriguez S, Martino R, Salinas T, Gimenez A, Hidalgo A . Human metapneumovirus infection in hematopoietic stem cell transplant recipients: high-resolution computed tomography findings. J Comput Assist Tomogr. 2005; 29(2):223-7. DOI: 10.1097/01.rct.0000157087.14838.4c. View